Más Dermatología, n.º 34

Armario-Hita JC et al. Dermatitis atópica Más Dermatol. 2021;34:5-13 doi:10.5538/1887-5181.2021.34.5 13 Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-82. 14. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwar- zenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Derma- tol. 2014;71(1):116-32. 15. Werfel T, Layton G, Yeadon M, Whitlock L, Osterloh I, Jiménez P, et al. Efficacy and safety of the histamine H4 receptor an- tagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(5):1830-7.e4. 16. Lönndahl L, Holst M, Bradley M, Killasli H, Heilborn J, Hall MA, et al. Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis. Acta Derm Venereol. 2018; 98(3):324-8.

RkJQdWJsaXNoZXIy MTAyMDQzMg==